Routine childhood vaccinations do not raise the risk of epilepsy in young children, as per a recent study led by the US Centers for Disease Control and Prevention. The research, published in The Journal of Pediatrics, also indicated that the aluminum in vaccine adjuvants does not heighten the risk of this neurological condition.
The study, involving 2,089 children diagnosed with epilepsy between the ages of 1 year and less than 4 years, compared them with 20,139 children without epilepsy matched for age, sex, and healthcare site. The majority of the children were boys (54%) and aged between 1 year and 23 months (69%). The researchers noted no increased risk following the routine childhood vaccine schedule.
Researchers evaluated vaccine exposure by analyzing the routine childhood vaccine schedule and the cumulative aluminum exposure from vaccine adjuvants, measured in milligrams. Aluminum salts, commonly used as adjuvants in vaccines to boost immune response, include various formulations like aluminum hydroxide (AH), aluminum phosphate (AP), and others. Despite safety concerns, the study found no association between these measures and a higher epilepsy risk.
According to the team, children with established epilepsy risk factors, such as premature birth, prior history of epilepsy, or underlying neurological or medical conditions, had notably higher odds of developing epilepsy. A subgroup analysis suggested that very young infants (1 to 2 months old) who received vaccines with the adjuvant combination AH/AP appeared to have approximately double the odds of an epilepsy diagnosis, though not statistically significant.
The researchers emphasized that this study offers additional assurance regarding the safety of the childhood vaccine schedule, particularly important as vaccination coverage has declined in some populations. They believe these findings could aid healthcare providers in addressing parental concerns about potential epilepsy risks.
